Biotech

All Articles

AstraZeneca posts records on in-house competitors to AbbVie, Pfizer ADCs

.AstraZeneca has shared an early examine the functionality of its in-house antibody-drug conjugate (...

iTeos- GSK's TIGIT superstar presents purposeful improvement

.After declaring a stage 3 launch based upon favorable midstage end results, iTeos and also GSK are ...

More joint FDA can speed up rare condition R&ampD: file

.The FDA needs to be actually even more open as well as joint to let loose a rise in commendations o...

Zenas, MBX, Bicara scalp to Nasdaq in scorching day for biotech IPOs

.It is actually an extraordinarily hectic Friday for biotech IPOs, with Zenas BioPharma, MBX and Bic...

Atea's COVID antiviral falls short to halt hospital stays in stage 3

.Atea Pharmaceuticals' antiviral has neglected yet another COVID-19 test, yet the biotech still hold...

Neurocrine's proposal to conserve schizophrenia possibility neglects

.Neurocrine Biosciences' schizophrenia program pivot has fallen short. The biotech was not able to d...

Sanofi pays $110M upfront for late-stage radioligand treatment

.Sanofi has actually brought in a late entrance to the radioligand event, paying for one hundred tho...

F 2G brings up $100M for 2nd attempt to obtain new antifungal to market

.After F2G's initial effort to obtain a new training class of antifungal to market was hindered due ...

Moderna targets $1.1 B in R&ampD spending slices, falls 5 systems amidst earnings pressures

.Moderna has sworn to cut R&ampD costs by $1.1 billion through 2027. The decision to retract the fin...

Sanofi's $80M bet on Fulcrum dystrophy medication ends in stage 3 fail

.Merely four months after Sanofi bet $80 million in upfront cash on Key Therapeutics' losmapimod, th...